Business Strategy Recommendation for Pfizer Inc.

The below presentation is the final term project for the spring 2023 interdisciplinary BPL 5100 - Business Policy course at Baruch College.

With the goal of solving strategic issues for a specific US company, our team examined Pfizer Inc.'s 2023 corporate finances and product pipeline leading to the recommendation for the acquisition of a smaller biotech firm. Given the extensive cash reserves resulting from COVID-19 vaccine revenues as well as the pending expiration of several high-revenue drugs, we recommended the investment in either Seagen Inc. or BeiGene Inc. for strategic positioning. Both firms had extensive portfolios with several oncology pharmaceuticals in the later development stages. As such they offered to complement Pfizer's strategic position perfectly.

In December of 2023, Pfizer completed the acquisition of Seagen Inc.

Team member names have been redacted for privacy considerations.